Patients must not have poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid and small cell carcinoma
Participants must have histologically or cytologically confirmed low- to intermediate-grade neuroendocrine tumor (carcinoid tumor)
Participants must have histologically confirmed well differentiated or moderately differentiated neuroendocrine tumor from either a primary or metastatic site; carcinoid tumors of any primary site are eligible
Poorly differentiated carcinoma, high grade neuroendocrine tumor or small cell carcinomas are excluded from this study
Neuroendocrine Tumors (well- and moderately-differentiated) of the lung, appendix, small intestine, colon, rectum, or pancreas
Histological or cytological proof of chemotherapy-naive, extensive, small cell lung cancer or neuroendocrine cancers that are either high grade or poorly differentiated
Have a histologically proven well-differentiated neuroendocrine tumor (World Health Organization [WHO] grade 1, grade 2, or morphologically and/or clinically well-differentiated grade 3)
Histopathologically confirmed, well-­differentiated metastatic NETs
Documentation of Disease:\r\n* Histologic Documentation: Well- or moderately-differentiated neuroendocrine tumors of pancreatic and non-pancreatic (i.e. carcinoid) origin by local pathology\r\n** The pathology report must state ONE of the following: 1) well- or moderately-differentiated neuroendocrine tumor, 2) low- or intermediate-grade neuroendocrine tumor, or 3) carcinoid tumor or atypical carcinoid tumor; documentation of histology from a primary or metastatic site is allowed\r\n** Patients with poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid tumor, or goblet cell carcinoid tumor are not eligible\r\n* Stage: Locally advanced/unresectable or metastatic disease\r\n* Tumor Site: Histological documentation of neuroendocrine tumor of pancreatic, gastrointestinal (GI), lung, or unknown primary site; GI, lung, and unknown primary NETs will enroll in the carcinoid tumor cohort of the study\r\n** Functional (associated with a clinical hormone syndrome) or nonfunctional tumors are allowed\r\n* Radiologic Evaluation: Target lesions must have shown evidence of disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria in the 12 months prior to registration; the radiologic images, imaging reports, and clinic notes indicating growth of existing lesions, development of new lesions, or treatment changes must be submitted
Metastatic poorly differentiated and/or high-grade neuroendocrine tumor/carcinoma originating outside of the lung (including unknown primary)
A pathologically confirmed (histology or cytology) malignant neoplasm that is determined to be well-differentiated neuroendocrine tumor (i.e. grade 1 or grade 2); the primary tumor location should be known or believed to be midgut
Patients with documentation of well differentiated liposarcoma only (of the well differentiated/dedifferentiated liposarcoma family) are specifically excluded, owing to its characteristically slow growth. If high grade areas are suspected (dedifferentiation), but not proved by pathology analysis (e.g. after primary resection of a well-differentiated liposarcoma), a biopsy must be performed to demonstrate the high-grade dedifferentiated disease
Patients must have histological evidence of a metastatic well differentiated or moderately differentiated mucinous appendiceal epithelial neoplasm (AEN)
Have metastatic and/or unresectable pathologically confirmed well-differentiated, typical or atypical neuroendocrine tumor of the lung
Histologic evidence of Well differentiated Neuroendocrine tumors (NETs) of the lung (typical and atypical according to the World Health Organisation (WHO criteria), evaluated locally)
Poorly differentiated or high grade carcinoma, or patients with neuroendocrine tumors not of lung origin are excluded
Well-differentiated (G1 or G2) based on local pathology report, non-functional neuroendocrine tumor of GI, pancreatic or thoracic (including lung and thymus) origin.
Poorly-differentiated GEP-NEC based on local pathology report
Poorly-differentiated GEP-NEC group: Disease progression while on or after prior treatment.
Well-differentiated grade 3 neuroendocrine tumors; poorly-differentiated neuroendocrine carcinoma of any origin (other than GEP-NEC); including NEC of unknown origin, adenocarcinoid, and goblet cell carcinoid
Chordoma (poorly differentiated or de-differentiated)
Subjects with a history of endometrial cancer are eligible only if they presented with a stage lower than 1A and if the histology was a subtype other than poorly differentiated
Patient must have histologically or cytologically confirmed well differentiated or moderately differentiated (low grade or intermediate grade) neuroendocrine tumor that is locally advanced or metastatic and not of pancreatic origin
Neuroendocrine tumors, pancreatic basket\r\n* Grade 1 or grade 2 (or described as low grade, intermediate grade, well differentiated, or moderately differentiated) according to reviewing pathologist\r\n* Progressive disease over the preceding 12 months\r\n* Any number of prior therapies, including 0\r\n* Patients using a somatostatin analogue for symptom control must be on stable doses for 56 days prior to enrollment
Neuroendocrine tumors, extrapancreatic basket\r\n* Grade 1 or grade 2 (or described as low grade, intermediate grade, well differentiated, or moderately differentiated; typical or atypical carcinoid if originating in lung) according to reviewing pathologist\r\n* Progressive disease over the preceding 12 months\r\n* Any number of prior therapies, including 0\r\n* Patients using a somatostatin analogue for symptom control must be on stable doses for 56 days prior to enrollment
Patients with well-differentiated neuroendocrine carcinoma (carcinoid tumor)
Histologically or cytologically confirmed metastatic and/or unresectable progressive, well differentiated carcinoid or pancreatic neuroendocrine tumor (NET) carcinoids
Histologically or cytologically confirmed low or intermediate grade, unresectable well differentiated foregut neuroendocrine tumors (thymic, bronchopulmonary, gastric, duodenal and pancreatic); patients with multiple neuroendocrine tumors associated with MEN1 syndrome will be eligible
Low- or intermediate-grade neuroendocrine carcinoma, including the following subtypes: carcinoid tumor, low- to intermediate-grade or well- to moderately-differentiated neuroendocrine carcinoma or tumor, atypical carcinoid tumor; documentation from a primary tumor or metastatic site is sufficient; patients with poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid tumor, or goblet cell carcinoid tumor are not eligible
Histologic documentation of well differentiated or moderately differentiated locally unresectable or metastatic pancreatic neuroendocrine tumor from either a primary or metastatic site with documented disease progression =< 12 months prior to enrollment with whose disease is not currently amenable to surgery, radiation or modality therapy with curative intent; if different histologic classification schemes are used, equivalent histologic classifications (for example “grade 1,” “low grade,” or “intermediate grade”) are allowed; there must be histologic documentation of a pancreatic primary site or clinical evidence of a pancreatic neuroendocrine primary tumor as determined by the treating physician; documentation from a metastatic site is sufficient if there is clinical evidence of a pancreatic primary site; in the case of discordant pathology, patient eligibility will be determined by the principal investigator (PI) after review of available records; patients with neuroendocrine tumors (e.g., gastrinoma, vasoactive intestinal peptidase [VIPoma]) in whom a pancreatic or peripancreatic primary site is strongly suspected are also eligible
Poorly differentiated neuroendocrine carcinoma or small cell carcinoma
Patient must have a histologically or cytologically confirmed diagnosis of pancreatic cancer or poorly differentiated neuroendocrine tumor and must have been treated with a regimen with known benefit for pancreatic cancer/poorly differentiated neuroendocrine tumor (MTD expansion cohort only)
Poorly differentiated or high grade pancreatic neuroendocrine tumors
Locally unresectable or metastatic, histologically-confirmed, carcinoid or pancreatic neuroendocrine tumor; tumors must be considered well- or moderately-differentiated; patients with poorly differentiated neuroendocrine carcinoma are excluded from the study
For patients with carcinoid tumors, patients must have progressed on, be currently receiving, or be intolerant to octreotide therapy; for patients with pancreatic neuroendocrine tumors, the prior or current use of octreotide or somatostatin analogues is permitted, but not required; if the patient is on octreotide, regardless of whether the patient has a carcinoid or pancreatic neuroendocrine tumor, the patient must be on a stable dose of somatostatin analogue for at least two months
High grade or poorly differentiated neuroendocrine tumors
Well-differentiated liposarcoma or atypical lipomatous tumor
High grade or poorly differentiated NET
Patients must have histologically or cytologically confirmed low or intermediate grade pancreatic NET; patients with neuroendocrine tumors associated with multiple endocrine neoplasia type 1 (MEN1) syndrome will be eligible
Histologically or cytologically confirmed well differentiated low or intermediate grade (World Health Organization [WHO] Grade 1 or 2) NET of pancreatic, gastrointestinal, lung, or undetermined origin that is locally advanced or metastatic and has progressed within the past 12 months
The participant has well-differentiated or moderately-differentiated, histologically confirmed neuroendocrine carcinoma, including carcinoid of any location and islet cell tumors
Pathologically confirmed metastatic unresectable well differentiated (low grade and intermediate grade) neuroendocrine tumors (Ki-67 < 20% and mitotic rate < 2 per 10 high power field) that demonstrate progressive disease (by serial computed tomography [CT] or magnetic resonance imaging [MRI] scans) in past 12 months including\r\n* Carcinoid tumors originating anywhere in the body including the gastrointestinal (GI) tract or bronchial tree or thymus\r\n* Pancreatic neuroendocrine tumors (including functional and non-functional islet cell, insulinomas and glucagonomas)\r\n* Pheochromocytomas\r\n* Gastrinomas (Zollinger-Ellison syndrome)\r\n* Multiple endocrine neoplasia (MEN type I/II),\r\n* Adrenal carcinomas with NET markers by immunohistochemistry (IHC) or serum\r\n* Somatostatinoma\r\n* VIPoma (vasoactive intestinal peptide)\r\n* Merkel cell tumors\r\n* Medullary thyroid carcinoma\r\n* Neuroendocrine tumors of unknown primary site
Histologic diagnosis of a well- to moderately differentiated PNET (low-intermediate grade); NOTE: pathology report should state one of the following: low-grade, intermediate grade, moderately- or well-differentiated NET, pancreatic NET (or neuroendocrine carcinoma of the pancreas); patients who have tumors with a Ki67 of 20 % - 30 % are eligible if the pathologist determines the tumor has the appearance of a well- to moderately differentiated neuroendocrine tumor
Patient's malignancy is consistent with well differentiated neuroendocrine (carcinoid) histology
PHASE I: Eligible patients include patients with histologically proven neuroendocrine tumors (paraganglioma, PHEO [pheochromocytoma], or well differentiated neuroendocrine tumor [NET] of the lung or gastrointestinal [GI] system) or neuroblastoma (NB); patients, who have NB, the diagnosis must be in accordance with the International Criteria, i.e., either histopathology or bone marrow involvement; patients must be able to undergo PET scan without sedation
Patients malignancy consistent with well differentiated (carcinoid) neuroendocrine histology
Has a metastatic neuroendocrine histology with MSKCC pathology confirmation as moderately or poorly differentiated or intermediate or high grade
Patients with poorly differentiated pancreatic neuroendocrine tumors (according to WHO 2000 classification).